- 1,876,070 new shares to be acquired by Chindex Hong Kong Limited (Fosun-group)

Kleinostheim, 13 November 2017 - The Management Board of curasan AG (ISIN DE0005494538) today, with the consent of the Supervisory Board, decided to fully implement also the second tranche of the capital increase with subscription rights agreed on 4 September 2017 and to stipulate its final volume to EUR 4,151,856.00. This way, the share capital of curasan AG, already increased by the first tranche of the capital increase with subscription rights to EUR 13,693,396.00 will be increased by nominal EUR 1,876,070.00 by the issuance of 1,876,070 new bearer shares (with a calculated share of the share capital of EUR 1.00 per share) against cash contributions. All new shares will carry dividend rights from 1 January 2017.

The shares were offered to the existing shareholders from 11 September to 25 September 2017 by way of indirect subscription right in a 22:8 ratio. During the subscription period subscription rights were exercised for 2,275,786 new shares. The remaining 1,876,070 new shares are to be acquired by Chindex Hong Kong Limited, a subsidiary of the Chinese Fosun-group on the basis of an investment agreement signed on 4 September 2017 at a price of EUR 1.20.

The full implementation of the capital increase with subscription rights is expected to be entered into the commercial register on or around 17 November 2017. The new shares are expected to be included in the existing listing of the company's shares in the regulated market of the Frankfurt Stock Exchange around 23 November 2017.

Through the capital increase by subscription rights curasan AG generates total gross proceeds from both tranches of almost EUR 5 million. This is primarily to be used for further market development in Asia and North America.

Also, with the start of the fourth quarter, Andrea Weidner, up to now responsible for Corporate Communications at curasan AG, has taken over responsibility for Investor Relations. Interim Manager Ingo Middelmenne who had headed the Investor Relations department since April 2015 will address himself to new tasks after the company's recently successfully completed capital increase, still supporting curasan in a consulting function.

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

Contact curasan AG:
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.de